We are N,N’-(4,6-Dichloropyrimidine-2,5-diyl)diformamide CAS:116477-30-6 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests
Chemical Name:N,N'-(4,6-Dichloropyrimidine-2,5-diyl)diformamide
CAS.NO: 116477-30-6
Synonyms:
5-((4-ethylpiperazin-1-yl)methyl)pyridin-2-amine
5-(4-ethyl-piperazin-1-ylmethyl)-pyridin-2-ylamine
Molecular Formula: C6H4Cl2N4O2
Molecular Weight: 235.028
Physical and Chemical Properties:
Density:1.8±0.1 g/cm3
Boiling point: 546.2±60.0 °C at 760 mmHg
Melting point: /
Flash point: 284.1±32.9 °C
Refractive index: 1.706
Specification:
Appearance: /
Purity:≥98.0%
Packing:
25kg cardboard drum or according to customer specified requirements
Storage:Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:Intermediates of Abacavir CAS:136470-78-5.
Related News: Inceptua Medicines Access is a business unit of the Inceptua Group. It offers full access solutions for the design, implementation and delivery of Pre-approval and Medicines Access Programs on behalf of biopharmaceutical companies.11-fenil-11,12-dihidroindolo [2,3-a] carbazol CAS:1024598-06-8 Inceptua Medicines Access is a business unit of the Inceptua Group. It offers full access solutions for the design, implementation and delivery of Pre-approval and Medicines Access Programs on behalf of biopharmaceutical companies.N-(4'-bromo-[1,1'-biphenyl]-4-yl)-N-phenylnaphthalen-1-amine CAS:352359-42-3 Madeleine Roche, Associate Pharmaceutical Analyst at GlobalData, comments: “Within the top 20 global companies that spent the most on R&D in 2018, the top spender – despite having the second smallest annual revenue of the group at $15.28 billion – is Celgene, whose R&D spend was equal to 37% of its annual revenue.2,4-diaminofenol sulfato CAS:74283-34-4 Madeleine Roche, Associate Pharmaceutical Analyst at GlobalData, comments: “Within the top 20 global companies that spent the most on R&D in 2018, the top spender – despite having the second smallest annual revenue of the group at $15.28 billion – is Celgene, whose R&D spend was equal to 37% of its annual revenue.At present, China’s bulk drug industry is mainly focused on bulk drug substances, and there is huge room for development in terms of specialty drug substances and patented drug substances.
Product Name | |
---|---|
3-Bromo-4-chloropyridine | View Details |
1-fluoro-2,4-bis(trifluoromethyl)benzene | View Details |
4-AMINODIPHENYLAMINE SULFATE Cas:71005-33-9 | View Details |